The efficacy of CDK4/6 inhibitors in the treatment of HR+/HER2- breast cancer demonstrates the success of applying basic knowledge of cell cycle regulation to the generation of clinically-relevant drugs. Here, ERBB2 is linked to breast carcinoma.